XML 62 R9.htm IDEA: XBRL DOCUMENT v3.20.1
ACQUISITIONS, DIVESTITURES AND OTHER ARRANGEMENTS (Notes)
 3 Months Ended
Mar. 31, 2020
Acquisitions, Divestitures and Other Arrangements [Abstract]  
Mergers, Acquisitions and Dispositions Disclosures [Text Block] ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS

Acquisitions

Business Combination

Celgene

On November 20, 2019, BMS completed the Celgene acquisition. The acquisition is expected to further position BMS as a leading biopharmaceutical company for sustained innovation and long-term growth and to address the needs of patients with cancer, inflammatory, immunologic or cardiovascular diseases through high-value innovative medicines and leading scientific capabilities. The transaction was accounted for as a business combination, which requires that assets acquired and liabilities assumed be recognized at their fair value as of the acquisition date. The purchase price allocation is preliminary and subject to change, including the valuation of inventory, property, plant and equipment, intangible assets, income taxes and legal contingencies among other items. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date. Measurement period adjustments increased goodwill by $22 million in the first quarter of 2020 due to purchase price allocation increases of $58 million to equity investments and $30 million to legal contingency liabilities, net of deferred income taxes.

Divestitures

The following table summarizes the financial impact of divestitures including royalties, which are included in Other expense/(income), net. Revenue and pretax earnings related to all divestitures and assets held-for-sale were not material in all periods presented (excluding divestiture gains or losses).
 
Three Months Ended March 31,
 
Net Proceeds(a)
 
Divestiture Gains
 
Royalty Income
Dollars in Millions
2020
 
2019
 
2020
 
2019
 
2020
 
2019
Diabetes Business
$
153

 
$
164

 
$
—

 
$
—

 
$
(127
)
 
$
(165
)
Erbitux*
4

 
5

 
—

 
—

 
—

 
—

Manufacturing Operations
—

 
2

 
(1
)
 
—

 
—

 
—

Plavix* and Avapro*/Avalide*
7

 
—

 
(12
)
 
—

 
—

 
—

Mature Brands and Other
31

 
—

 
(3
)
 
—

 
(31
)
 
(1
)
Total
$
195

 
$
171

 
$
(16
)
 
$
—

 
$
(158
)
 
$
(166
)
(a)
Includes royalties received subsequent to the related sale of the asset or business.